362 related articles for article (PubMed ID: 23439499)
1. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
[TBL] [Abstract][Full Text] [Related]
2. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.
Guo ZS; Parimi V; O'Malley ME; Thirunavukarasu P; Sathaiah M; Austin F; Bartlett DL
Gene Ther; 2010 Dec; 17(12):1465-75. PubMed ID: 20703311
[TBL] [Abstract][Full Text] [Related]
3. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
[TBL] [Abstract][Full Text] [Related]
4. Replicating poxviruses for human cancer therapy.
Kim M
J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
[TBL] [Abstract][Full Text] [Related]
5. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
[TBL] [Abstract][Full Text] [Related]
7. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Kirn DH; Thorne SH
Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
[TBL] [Abstract][Full Text] [Related]
8. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
9.
Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
Front Immunol; 2021; 12():610042. PubMed ID: 33679747
[TBL] [Abstract][Full Text] [Related]
10. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ; Thorne SH; Bell JC; Kirn DH
Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
12. Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan.
Yu J; Li Y; Zhong M; Yang J; Zhou D; Zhao B; Cao Y; Yan H; Zhang E; Yang Y; Feng Z; Qi X; Yan H
Antiviral Res; 2018 May; 153():49-59. PubMed ID: 29550516
[TBL] [Abstract][Full Text] [Related]
13. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
14. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
[TBL] [Abstract][Full Text] [Related]
15. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
[TBL] [Abstract][Full Text] [Related]
17. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
[TBL] [Abstract][Full Text] [Related]
18. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.
Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM
Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
[No Abstract] [Full Text] [Related]
20. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.
Chen NG; Yu YA; Zhang Q; Szalay AA
J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
